Antihypertensive prescription in pediatric dialysis: A practitioner survey by the Midwest Pediatric Nephrology Consortium study

Hemodialysis International

Volumn 13, Issue 3, 2009, Pages 307-315

  Lin, Jen Jar ^a   Mitsnefes, Mark M ^b   Smoyer, William E ^c   Valentini, Rudolph P ^d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

Hemodialysis; Hypertension; Pediatric patients; Peritoneal dialysis

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; FOSINOPRIL; HYDRALAZINE; LABETALOL; LISINOPRIL; METOPROLOL; MINOXIDIL; NADOLOL; NIFEDIPINE; PRAZOSIN; PROPRANOLOL; RAMIPRIL; TIMOLOL; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT; VERAPAMIL;

ARTICLE; CHILD CARE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HEALTH SURVEY; HEMODIALYSIS PATIENT; HUMAN; NEPHROLOGIST; PERITONEAL DIALYSIS; PRESCRIPTION; QUESTIONNAIRE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CHILD; HUMANS; HYPERTENSION; NEPHROLOGY; PEDIATRICS; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; RENAL DIALYSIS; UNITED STATES;

EID: 69249164172     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00392.x     Document Type: Article

References (41)

1. Mailloux LU, Haley WE. Hypertension in the ESRD patient: Pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis. 1998; 32:705-719.
2. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int. 2002; 62:1784-1790.
3. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003; 115:291-297.
4. Salem MM. Hypertension in the hemodialysis population: A survey of 649 patients. Am J Kidney Dis. 1995; 26:461-468.
5. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 1996; 49:1379-1385.
6. Mitsnefes M, Stablein D. Hypertension in pediatric patients on long-term dialysis: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Kidney Dis. 2005; 45:309-315.
7. Wang MC, Tseng CC, Tsai WC, Huang JJ. Blood pressure and left ventricular hypertrophy in patients on different peritoneal dialysis regimens. Perit Dial Int. 2001; 21:36-42.
8. Rahman M, Griffin V, Heyka R, Hoit B. Diurnal variation of blood pressure; reproducibility and association with left ventricular hypertrophy in hemodialysis patients. Blood Press Monit. 2005; 10:25-32.
9. Liu M, Takahashi H, Morita Y, et al. Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients. Nephrol Dial Transplant. 2003; 18:563-569.
10. Mancia G, Parati G, di Rienzo M, Zanchetti A. Blood pressure variability. In: Mancia G, Zanchetti A, eds. Handbook of Hypertension: Pathophysiology of Hypertension. Amsterdam: Elsevier Science; 1997:117-169.
11. Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens. 2003; 21:1961-1967.
12. Miao CY, Xie HH, Zhan LS, Su DF. Blood pressure variability is more important than blood pressure level in determination of end-organ damage in rats. J Hypertens. 2006; 24:1125-1135.
13. Pringle E, Phillips C, Thijs L, et al. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens. 2003; 21:2251-2257.
14. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: Impact on the early morning period. Am J Hypertens. 2004; 17:347-353.
15. Charra B, Chazot C. Volume control, blood pressure and cardiovascular function. Lessons from hemodialysis treatment. Nephron Physiol. 2003; 93:94-101.
16. Santos SF, Mendes RB, Santos CA, Dorigo D, Peixoto AJ. Profile of interdialytic blood pressure in hemodialysis patients. Am J Nephrol. 2003; 23:96-105.
17. Horl MP, Horl WH. Hemodialysis-associated hypertension: Pathophysiology and therapy. Am J Kidney Dis. 2002; 39:227-244.
18. Tkaczyk M, Nowicki M, Balasz-Chmielewska I, et al. Hypertension in dialysed children: The prevalence and therapeutic approach in Poland-a nationwide survey. Nephrol Dial Transplant. 2006; 21:736-742.
19. Augustyniak RA, Tuncel M, Zhang W, Toto RD, Victor RG. Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens. 2002; 20:3-9.
20. Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J Hypertens. 2002; 20:2183-2189.
21. Nishikimi T, Minami J, Tamano K, et al. Left ventricular mass relates to average systolic blood pressure, but not loss of circadian blood pressure in stable hemodialysis patients: An ambulatory 48-hour blood pressure study. Hypertens Res. 2001; 24:507-514.
22. Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis. 2002; 40:1023-1029.
23. Suzuki H, Kanno Y, Kaneko K, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial. 2004; 8:320-327.
24. Cice G, Ferrara L, Di Benedetto A, et al. Dilated cardiomyopathy in dialysis patients-Beneficial effects of carvedilol: A double-blind, placebo-controlled trial. J Am Coll Cardiol. 2001; 37:407-411.
25. Hara Y, Hamada M, Shigematsu Y, Murakami B, Hiwada K. Beneficial effect of beta-adrenergic blockade on left ventricular function in haemodialysis patients. Clin Sci (Lond). 2001; 101:219-225.
26. Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverso GB. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int. 1993; 44:881-886.
27. Fourtillan JB, Ingrand I, Decourt JP, Istin B, Girault J. The kinetic profiles of amlodipine and of a sustained release form of diltiazem. Therapie. 1998; 53:121-126.
28. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens. 1993; 11:1133-1137.
29. Parati G. Blood pressure variability: Its measurement and significance in hypertension. J Hypertens. 2005; 23(Suppl):S19-S25.
30. Leypoldt JK, Cheung AK, Delmez JA, et al. Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int. 2002; 61:266-275.
31. Kojima M, Taniguchi M, Sato K, Ueda R, Dohi Y. Antihypertensive effects of long-acting calcium channel blockers on hemodialysis days-a randomized crossover trial between benidipine and nifedipine CR. Nephron Clin Pract. 2004; 97:c49-c53.
32. Leenen FH, Myers MG, Joyner CD, Toal CB. Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril. Can J Cardiol. 2002; 18:1285-1293.
33. Tisler A, Akocsi K, Harshegyi I, et al. Comparison of dialysis and clinical characteristics of patients with frequent and occasional hemodialysis-associated hypotension. Kidney Blood Press Res. 2002; 25:97-102.
34. Rostoker G, Griuncelli M, Benmaadi A. Candesartan cilexetil on regular hemodialysis: Inability to reduce excessive thirst, but good tolerance and efficacy in hypertensive patients. Ren Fail. 2006; 28:283-286.
35. Leenen FH, Fourney A, Notman G, Tanner J. Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol. 1996; 41:83-88.
36. Gunal AI, Duman S, Ozkahya M, et al. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis. 2001; 37:588-593.
37. Koc M, Toprak A, Tezcan H, Bihorac A, Akoglu E, Ozener IC. Uncontrolled hypertension due to volume overload contributes to higher left ventricular mass index in CAPD patients. Nephrol Dial Transplant. 2002; 17:1661-1666.
38. Holtta T, Happonen JM, Ronnholm K, Fyhrquist F, Holmberg C. Hypertension, cardiac state, and the role of volume overload during peritoneal dialysis. Pediatr Nephrol. 2001; 16:324-331.
39. Witte K, Weisser K, Neubeck M, et al. Cardiovascular effects, pharmacokinetics, and converting enzyme inhibition of enalapril after morning versus evening administration. Clin Pharmacol Ther. 1993; 54:177-186.
40. Palatini P, Racioppa A, Raule G, Zaninotto M, Penzo M, Pessina AC. Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril. Clin Pharmacol Ther. 1992; 52:378-383.
41. Palatini P, Mos L, Motolese M, et al. Effect of evening versus morning benazepril on 24-hour blood pressure: A comparative study with continuous intraarterial monitoring. Int J Clin Pharmacol Ther Toxicol. 1993; 31:295-300.